You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

adjuvant or neoadjuvant

Showing 1 - 25 of 7,678
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant

Not yet recruiting
  • BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
  • Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
  • Bobigny, France
    Hospitl Avicenne
Sep 13, 2023

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Brain Metastases, Radiotherapy Trial in Heidelberg (Preoperative Radiotherapy, Intraoperative Radiation, Postoperative

Not yet recruiting
  • Brain Metastases
  • Radiotherapy
  • Preoperative Radiotherapy
  • +2 more
  • Heidelberg, Germany
    Department of Radiotherapy, University of Heidelberg
May 12, 2023

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Penpulimab injection, cisplatin, albumin-paclitaxel)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Penpulimab injection
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University
Oct 7, 2023

NSCLC, Stage II-IIIA, Immunotherapy Trial in Shanghai (Serplulimab and Chemotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • +3 more
  • Serplulimab and Chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 27, 2023

Pancreatic Cancer Trial in United States (Gemcitabine and Capecitabine)

Recruiting
  • Pancreatic Cancer
  • Gemcitabine and Capecitabine
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Dec 31, 2022

Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas Trial in Ulm (perioperative nab-paclitaxel/gemcitabine,

Completed
  • Resectable Pancreatic Cancer
  • Ductal Adenocarcinoma of the Pancreas
  • perioperative nab-paclitaxel/gemcitabine
  • adjuvant nab-paclitaxel/gemcitabine
  • Ulm, Germany
    University of Ulm, Dept. of Internal Medicine I
Nov 21, 2022

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 22, 2023

Melanoma, Squamous Cell Carcinoma of Head and Neck Trial (IO102-IO103, Pembrolizumab)

Not yet recruiting
  • Melanoma
  • Squamous Cell Carcinoma of Head and Neck
  • (no location specified)
Nov 7, 2022

Esophageal Cancer, Surgery, Neoadjuvant Treatment Trial in Zhengzhou (Neoadjuvant immunochemo)

Recruiting
  • Esophageal Cancer
  • +3 more
  • Neoadjuvant immunochemotherapy
  • Zhengzhou, Henan, China
    Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzh
Oct 2, 2022

Non Small Cell Lung Cancer Trial in Innsbruck (neoadjuvant therapy with Pembrolizumab/Lenvatinib, Surgery, Adjuvant Treatment

Recruiting
  • Non Small Cell Lung Cancer
  • neoadjuvant therapy with Pembrolizumab/Lenvatinib
  • +2 more
  • Innsbruck, Tirol, Austria
    Medical University Innsbruck
Aug 23, 2022

Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

Not yet recruiting
  • Stage IIIB(N2) Non-small Cell Lung Cancer
  • +3 more
  • Pembrolizumab 200 mg IV infusion
  • Beijing, Beijing, China
    Peking University
May 30, 2023

Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,

Not yet recruiting
  • Pancreatic Cancer, Stage IB
  • +3 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jan 4, 2023

Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor Trial in Beijing (Pembrolizumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
May 17, 2022

Albumin Binding Paclitaxel Compared With Common Paclitaxel in

Recruiting
  • Breast Cancer
  • Jinan, Shandong, China
    The First Affiliated Hospital of Shandong First Medical Universi
Nov 24, 2022

Minimally Residual of Esophageal Cancer 001

Recruiting
  • Esophageal Carcinoma
  • Minimal Residual Disease
    • Shijiazhuang, Hebei, China
      Fourth Hospital of Hebei Medical University
    Jul 17, 2023

    Bladder Cancer Trial in Aarhus (Mitomycin c)

    Active, not recruiting
    • Bladder Cancer
    • Mitomycin c
    • Aarhus, Denmark
      Aarhus University Hospital
    Aug 5, 2022

    Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

    Not yet recruiting
    • Renal Cell Carcinoma
    • Neoadjuvant Lenvatinib
    • +3 more
    • (no location specified)
    Dec 23, 2022

    To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast

    Not yet recruiting
    • To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
    • Monosialotetrahexose ganglioside sodium injection
    • (no location specified)
    Mar 27, 2023

    Gastric Cancer Trial in Fuzhou (response to neoadjuvant chemo)

    Completed
    • Gastric Cancer
    • response to neoadjuvant chemotherapy
    • Fuzhou, Fujian, China
      Department of Gastric Surgery
    Jul 15, 2022

    Ocular Melanoma Trial in Sydney, Melbourne (Darovasertib)

    Recruiting
    • Ocular Melanoma
    • Sydney, New South Wales, Australia
    • +1 more
    May 3, 2022

    Bladder Urothelial Carcinoma Trial in Nanjing (primary focal resection plus lymph node dissection, Tislelizumab, Gemcitabine

    Recruiting
    • Bladder Urothelial Carcinoma
    • primary focal resection plus lymph node dissection
    • +2 more
    • Nanjing, Jiangsu, China
      The first affiliated hospital of Nanjing Medical University
    Dec 7, 2022

    NSCLC Trial (Atezolizumab, Tiragolumab)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Apr 5, 2023

    Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Toripalimab+cetuximab)

    Recruiting
    • Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
    • Shanghai, Shanghai, China
      the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
    Nov 1, 2022

    Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation Trial in Tampa (Encorafenib Pill, Binimetinib Pill, Nivolumab)

    Recruiting
    • Melanoma Stage III
    • +2 more
    • Encorafenib Pill
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    May 27, 2022